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Invasive fungal diseases, especially those caused by molds,show many similarities with lymphomas and other hema-tologic cancers. Indeed, unequivocal proof for the pres-
ence of these life-threatening diseases relies on histopatho-
logical evidence or on the demonstration of malignant cells or
fungi by microscopic examination or culture. In general, if left
untreated, these diseases will disseminate and prove fatal.
Before adequate treatment is started, a staging workup in
search of metastatic lesions needs to be performed, usually
involving (but not limited to) whole body computed tomog-
raphy (CT) scanning, with or without positron emission
tomography, and a thorough examination of sanctuary sites.
In addition, prognostic scores are constructed at baseline and
immunophenotypic profiles, cytogenetic, molecular or sero-
logic markers are identified. The latter may have prognostic
value or later serve as surrogate markers for detecting residual
disease or for guiding further therapy. First-line therapy typi-
cally consists of a single drug or combination of drugs, includ-
ing the use of monoclonal antibodies or immunomodulatory
drugs. Moreover, successful first-line therapy is frequently
followed by maintenance therapy for several months, with or
without adjunctive radiotherapy or surgery. In case of refrac-
tory disease or relapse, salvage treatment is started using
drugs with different modes of action. Finally, the crude mor-
tality rate of invasive fungal disease is not that different from
the mortality rate of most malignant blood disorders, being
around 40%. However, assessing the role of the underlying
malignant disease or of invasive fungal disease remains diffi-
cult, especially when a postmortem examination is not car-
ried out. 
Despite the obvious similarities, clinicians seem to accept
different thresholds for initiating diagnostic workups and for
starting treatment. Virtually no hemato-oncologist would
consider starting antineoplastic chemotherapy, immunother-
apy or radiotherapy to prevent the development of malignant
disease in a population at risk, or to ‘treat’ a strong clinical
suspicion that the patient may have malignant disease, even
if their decision is based on a marker in the absence of
histopathological evidence. However, a large majority of
these physicians are apparently willing to start expensive
broad-spectrum antifungal agents for these exact indications,
irrespective of the immediate and long-term consequences,
be they in terms of cost, the development of resistance or tox-
icity. This liberal approach developed in the early 1980s and
was fueled by the lack of reliable non-invasive diagnostic
tools, a reluctance to look for tissue-based evidence in
cytopenic patients, and the impression that early treatment
would result in better outcome. 
Over the last few decades, four basic strategies have been
developed and investigated in clinical studies to deal with
invasive fungal disease, particularly in neutropenic patients.
As far as invasive mold disease is concerned, it is possible to
delineate various patterns that are encountered in the neu-
tropenic population (Table 1) based on radiological signs and
clinical symptoms that might be consistent with invasive fun-
gal disease, and on mycology results, with a view to assessing
whether or not they are consistent with infection, disease or
both. Each pattern is evaluated for its compatibility with
infection and disease, and whether or not it meets the current
EORTC/MSG definitions.1 Management options are also
assigned to each pattern. The diagnosis is predicated from a
CT scan, and also by testing for evidence of infection directly
by culture, and indirectly by testing for galactomannan,
though PCR and beta-d-glucan might be included as well.
Categories from A through to E each progress along an axis
of certainty of diagnosis of invasive fungal disease. Whilst
category A represents no invasive fungal disease at all, cate-
gory E represents proven invasive fungal disease according to
current EORTC/MSG definitions. Categories B, C and D rep-
resent the spectrum in between these two extremes.
Category A is made up of patients who might be considered
suitable candidates for prophylaxis,2 and category B includes
those patients who typically receive empirical antifungal
therapy because of persistent unexplained fever despite treat-
ment with broad-spectrum antibacterial therapy.3 Although
there is no clinical or microbiological evidence of an invasive
fungal disease, this cannot be excluded. Category C merits a
more diagnostic-oriented approach (often erroneously called
‘pre-emptive’ therapy), while categories D and E would
receive directed treatment. In clinical practice, these strategies
are not mutually exclusive, but rather represent a continuous
spectrum of antifungal approaches which may show some
considerable overlap. More recently, the focus has clearly
shifted towards early antifungal intervention, especially in
view of the dismal outcome of treating more advanced inva-
sive fungal disease.  
The aim of antifungal prophylaxis (the use of antifungals
for patients considered to be at high-risk, usually at thera-
peutic doses, except for aerosolized formulations) is to pre-
vent invasive fungal infection occurring, or to prevent infec-
tions evolving into invasive fungal disease and to improve
short-term survival. This has best been demonstrated for flu-
conazole in stem cell transplant recipients4 and for posacona-
zole in acute myelogenous leukemia/myelodysplastic syn-
drome (AML/MDS) patients receiving remission-induction
chemotherapy.5 However, the apparent beneficial impact of
posaconazole prophylaxis on overall survival has never been
supported by a multivariable regression analysis that takes
into account the impact of the status and extent of the under-
lying disease that are probably the strongest predictors of
outcome. Moreover, the reduced incidence of invasive
Aspergillus disease in patients receiving a mold-active anti-
fungal may be partly explained by the lower performance
of the galactomannan ELISA assay in this setting. For
future studies, fungal colonization, incidence of invasive
fungal disease, and disease-free survival are probably
more appropriate end points than mortality, provided
that the study is performed in a blinded-fashion (prefer-
ably placebo-controlled) and incorporates a predefined
mandatory diagnostic algorithm in both study arms.
Infection-related end points are better indicators of pro-
phylactic effectiveness than mortality, as the latter is
strongly influenced by the status and severity of the
underlying disease. Nevertheless, an Australian observa-
tional study by Ananda-Rajah and colleagues comparing
fluconazole/itraconazole versus voriconazole/posacona-
zole prophylaxis in AML/MDS patients supports the
main findings of the clinical trial, namely a lower inci-
dence of breakthrough invasive fungal disease (including
possible diseases), and less empirical antifungal therapy.6
In addition, posaconazole prophylaxis also resulted in a
lower demand for CT scans, and when a chest CT scan
was taken, fewer lesions were seen. However, unselected
use of broad-spectrum antifungal prophylaxis also raises
concerns about expenditure, overtreatment, toxicity and
emergent drug-resistance. Furthermore, better knowledge
of institutional fungal epidemiology and further refine-
ments to the identification of patients most likely to ben-
efit from antifungal prophylaxis (i.e. what constitutes
high-risk in terms of likelihood of developing invasive
fungal disease and what is an acceptable number needed
to treat), would represent a major advance in our efforts
to reduce the drawbacks associated with routine prophy-
laxis. As a result, antifungal prophylaxis practice varies
considerably among different centers and remains the
subject of lively debate.7
For a long time, profound and prolonged neutropenia
accompanied by persistent or relapsing fever has been
regarded as a sufficient trigger for starting broad-spectrum
antifungals; a strategy referred to as empirical antifungal
therapy. This practice has never been supported by robust
scientific evidence and has important drawbacks, includ-
ing drug-related toxicity and increased cost. In spite of
this, the empirical use of antifungals has become the stan-
dard of care in many hematology centers. It was also
endorsed by consensus guidelines and is relied on by cen-
ters that have limited or no access to radiological and
mycological diagnostic tools. A prospective study from
Spain by Aguilar-Guisado and colleagues challenges this
undifferentiated approach.8 The study established the fea-
sibility of a more tailored diagnostic and therapeutic
approach based on clinical criteria other than fever. The
strategy had an excellent negative predictive value (correct
identification of patients not needing antifungal therapy)
for febrile neutropenic patients, resulting in a marked
reduction in antifungal consumption without an increase
in the overall mortality or fungal-related mortality. These
results are in line with those of other studies in this setting
using radiological features or microbiological test results
or both to trigger the initiation of antifungal therapy.9,10
However, despite the significant global reduction in anti-
fungal usage compared to the classic empirical approach,
these new strategies still have low specificity.
Consequently, a large proportion of patients will continue
to receive antifungal therapy unnecessarily. 
Given that the cupboard of antifungals is bare and there
are few in the pipeline, future efforts should focus on the
development and incorporation of tests to increase the
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Table 1. Patterns of invasive fungal disease in pratice, based on 2008 EORTC-MSG criteria.
specificity of the diagnostic approach. The availability of a
clinically validated test for detecting fungal DNA would
be very welcome. The adoption of explicit care pathways
would also help establish a standard that achieves a more
favorable balance between effectiveness and cost.11 It is
also true that there will be no paradigm shift without evi-
dence from properly conducted prospective strategy trials.
Non-randomized studies have identified some of the
logistical hurdles. For instance, a diagnostic-oriented
approach requires the availability of diagnostic tests with
a rapid turnaround and the full cooperation and compli-
ance of all parties involved (be they clinicians, microbiolo-
gists, radiologists, nurses, or pharmacists) as well as a strict
adherence to minimum standards of diagnosis as envis-
aged in integrated care pathways.12 Validation of these
more targeted approaches is clearly required, but will only
be possible if health care providers combine their efforts
with those of researchers to establish a consortium to sup-
port such studies. This is essential if we are to evaluate a
standardized diagnostic approach that has already gained
wide acceptance but has not yet been formally examined.
Fortunately, such endeavors are currently ongoing in
Europe; for instance, the multicenter strategic study of
empirical versus pre-emptive antifungal therapy of patients
with hematologic malignancies of the EORTC Infectious
Diseases Group. However, even if successful, this study
will likely only meet the needs of European institutions.
There is also a pressing need to explore antifungal strate-
gies in other clinical settings both in Europe and in other
parts of the world, as invasive fungal diseases are likely to
remain an unwelcome companion when treating malig-
nancies, managing immunodeficiencies, and delivering
transplants of stem cells and organs.  
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